此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Acute Effects of Jägermeister With Energy Drinks (Jägermbomb) (JB)

2026年5月8日 更新者:Fundació Institut Germans Trias i Pujol

Acute Effects of an Explosive Cocktail With Energy Drinks That is Trendy Among Young People, the Jägerbomb

The main objective of this study is to compare the acute effects of drinking Jägerbombs with drinking alcohol alone during a binge-drinking episode, which involves consuming a large amount of alcohol in a short period of time to become intoxicated. Secondary objectives are to assess whether Jägerbombs produce prototypical alcohol effects, increase stimulation and rewarding effects, affect coordination, time reaction and vision, change stress-related hormone responses, and cause hangover symptoms.

研究概览

详细说明

Alcohol use is very common among young people in Spain. Binge drinking is a pattern of alcohol consumption that raises blood alcohol concentration (BAC) to 0.08% or higher (0.4 mg/L in breath air), typically defined as drinking 5 or more standard drinks for men or 4 or more for women within about 2 hours.This is a serious public health problem because it can cause illness, injuries, and even death.

Energy drinks (ED) are also widely used by young people and are often mixed with alcohol. People do this to hide the taste of alcohol or to feel less tired or drunk. However, ED do not reduce alcohol intoxication and are linked to more risky behavior. Research suggests that ED only slightly reduce some alcohol-related problems, such as slower reactions. This can give a false feeling of safety and make people more likely to drive while drunk.

One popular mixture is the Jägerbomb, a combination of Jägermeister liquor and energy drink (ED), but its effects have not been previously studied.

This study will be conducted as a randomized, double-blind, placebo-controlled trial in healthy adults who have experience consuming alcohol and caffeinated beverages.

A pilot study has been conducted in the first four participants (two women and two men) using a dose of 55 g of alcohol.

研究类型

介入性

注册 (估计的)

24

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Barcelona、西班牙
        • 招聘中
        • Hospital Universitari Germans Trias i Pujol-IGTP
        • 首席研究员:
          • Clara Pérez-Mañá, MD, PhD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

Inclusion Criteria:

  1. Men and women between 18-45 years old with a weight between 50-90 kg for men and between 55-80 kg for women, and a body mass index (BMI) between 19-28 kg/m2. Lower or higher weights or BMIs are allowed, in the opinion of the Principal Investigator or the collaborators designated by the Principal Investigator and that do not pose a risk to the subjects and do not interfere with the objectives of the study.
  2. Alcohol consumption in the form of occasional binge drinking (≥1 time/month), social alcohol consumption (≥10g/day distributed weekly) and experience in alcohol intoxication.
  3. Consumption ≥7 drinks with methylxanthines (coffee, tea, chocolate, cola, BE) per week and who have consumed ED on at least one occasion.
  4. Understand and agree to the trial procedures and sign an informed consent.
  5. History and physical examination that demonstrate no organic or psychiatric disorders.
  6. The ECG and general blood and urine tests performed before the test should be within normal limits. Minor or punctual variations from the limits of normality are allowed if, at the discretion of the Principal Investigator, taking into account the state of science, they are not of clinical significance, do not pose a risk to the subjects and do not interfere with the assessment of the product. These variations and their non-relevance will be justified in writing in a specific way.

Exclusion Criteria:

  1. Not meeting the inclusion criteria.
  2. History or clinical evidence of gastrointestinal, liver, renal or other disorders that may involve an alteration in the absorption, distribution, metabolism or excretion of the drug, or that are suggestive of gastrointestinal irritation by drugs.
  3. Current history of substance use disorder according to DSM-V (except nicotine). A previous history of mild substance use disorder (corresponding to substance abuse according to DSM-IV criteria) is admitted.
  4. History or clinical evidence of psychiatric disorders, alcoholism, abuse of drugs or other drugs or habitual consumption of psychoactive drugs.
  5. Have participated in clinical trials with drugs or nutraceuticals in the previous 12 weeks.

5) Have suffered any organic disease or major surgery in the three months prior to the start of the study.

6) Subjects who have an intolerance or have had serious adverse reactions to alcohol. The inclusion of subjects of oriental origin who do not have an intolerance to alcohol will be allowed.

7) Have taken medication regularly in the month prior to the study sessions, with the exception of vitamins, herbal remedies, or dietary supplements that, in the judgment of the Principal Investigator or collaborators designated by the Principal Investigator, do not pose a risk to the subjects and do not interfere with the objectives of the study. Treatment with single doses of symptomatic medication in the week prior to study sessions will not be grounds for exclusion if it is assumed to have been completely eliminated on the day of the experimental session.

8) Smokers of >5 cigarettes a day. 9) Consumption of more than 20 g of alcohol daily in women and more than 40 g in men.

10) Consumers of more than 5 coffees, teas, colas, or other stimulant or xanthine beverages daily in the 3 months prior to the start of the study.

11) Subjects who are not able to understand the nature of the trial and the procedures they are asked to follow.

12) Subjects with positive serology for hepatitis B, C or HIV. 13) Women who are pregnant or breastfeeding, or who use hormonal contraceptives or do not use reliable contraceptive measures during the study (such as abstinence, intrauterine devices, barrier methods or with a vasectomized partner).

14) Women with amenorrhea or premenstrual syndrome of severe intensity.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Alcohol (Jägermeister) and Energy Drink: Jägerbomb
The total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Jägermeister 196 mL (ethanol 55 g) + ED 625 ml (200 mg caffeine). Men: Jägermeister 250 mL (ethanol 70 g) + ED 625 ml (200 mg caffeine)
Multiple oral dose of Jägermeister mixed with ED
有源比较器:Alcohol (Jägermeister) and Energy Drink Placebo
The total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Jägermeister 196 mL (55 g of ethanol) + placebo ED (a non-caffeinated soft drink) 625 mL. Men: Jägermeister 250 mL (70 g) + placebo ED (a non-caffeinated soft drink) 625 mL.
Multiple oral dose of Jägermeister mixed with a placebo of ED (non-caffeinated soft drink)
安慰剂比较:Alcohol placebo and Energy Drink Placebo
The total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Ethanol placebo (water) + ED placebo (a non-caffeinated soft drink) 625 mL. Men: Ethanol placebo (water) + ED placebo (a non-caffeinated soft drink) 625 mL.
Multiple oral dose of alcohol placebo (water) mixed with ED placebo (non-caffeinated soft drink)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in reaction time (Psychomotor Vigilance Task)
大体时间:From baseline to 4 hours after administration
Test will be performed using a computer program. Mean and median latency will be assessed. Obtained baseline, 1.5 and 4-h after administration.
From baseline to 4 hours after administration

次要结果测量

结果测量
措施说明
大体时间
呼吸空气中乙醇达到最大浓度 (tmax) 的时间
大体时间:从基线到给药后 8 小时
呼吸空气中乙醇达到最大浓度 (tmax) 的时间
从基线到给药后 8 小时
Maximum concentration (Cmax) of ethanol in breath air
大体时间:From baseline to 8 hours after administration
Maximum concentration (Cmax) of ethanol in breath air
From baseline to 8 hours after administration
Maximum concentration (Cmax) of caffeine in oral fluid
大体时间:From baseline to 6 hours after administration
Maximum concentration (Cmax) of caffeine in oral fluid
From baseline to 6 hours after administration
Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations
大体时间:From baseline to 8 hours after administration
Obtained baseline and 0.17, 0.33 , 0.5, 0.66, 0,83, 1, 1.25, 1.5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Area under the concentration-time curve (AUC 0-6h) of caffeine oral fluid concentrations
大体时间:From baseline to 6 hours after administration
Calculation of AUC of caffeine concentrations obtained baseline and 1, 1.5, 2, 4, 6-h after administration.
From baseline to 6 hours after administration
Time to reach maximum concentration (tmax) of caffeine in oral fluid
大体时间:From baseline to 6 hours after administration
Time to reach maximum concentration (tmax) of caffeine in oral fluid
From baseline to 6 hours after administration
Maximum concentration (Cmax) of cortisol in oral fluid
大体时间:From baseline till 6 hours after administration
Maximum concentration (Cmax) of cortisol in oral fluid
From baseline till 6 hours after administration
Time to reach maximum concentration (tmax) of saliva in oral fluid
大体时间:From baseline to 6 hours after administration
Time to reach maximum concentration (tmax) of saliva in oral fluid
From baseline to 6 hours after administration
Area under the concentration-time curve (AUC 0-6h) of cortisol concentrations in oral fluid
大体时间:From baseline till 6 hours after administration
Calculation of AUC of cortisol oral fluid concentrations. Obtained baseline and 1, 1.5 , 2, 4, 6-h after administration.
From baseline till 6 hours after administration
Change in visual acuity
大体时间:From baseline to 4 hours after administration
A computer program will be used to measure static and dynamic visual acuity with different contrast (100% and 10%) at baseline, 2 and 4-h after administration
From baseline to 4 hours after administration
Change in unstable tracking task
大体时间:From baseline to 4 hours after administration
Test will be performed using a computer program. Mean lambda and number of errors will be measured. Obtained baseline and 1.5, 4-h after administration.
From baseline to 4 hours after administration
Change in pupillary diameter
大体时间:From baseline to 4 hours after administration
Pupillary diameter will be measured with a manual pupilometer
From baseline to 4 hours after administration
Change in drowsiness feeling
大体时间:From baseline to 8 hours after administration
Drowsiness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in drunkenness feeling
大体时间:From baseline to 8 hours after administration
Drunkenness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration
From baseline to 8 hours after administration
Change in dizziness feeling
大体时间:From baseline to 8 hours after administration
Dizziness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration
From baseline to 8 hours after administration
Change in palpitations reported by the participant
大体时间:From baseline to 8 hours after administration
Palpitations will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in anxiety feeling
大体时间:From baseline to 8 hours after administration
Anxiety will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in headache
大体时间:From baseline to 8 hours after administration
Headache will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in ability and predisposition to drive in certain situations
大体时间:From baseline to 6 hours after administration
Will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 1.5, 4, 6-h after administration.
From baseline to 6 hours after administration
Desire to keep drinking
大体时间:At 1.5 hours after administration
Will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained at the end of beverage administration. Only one measure at 1.5 hours.
At 1.5 hours after administration
Change in subjective effects measured with Addiction Research Center Inventory (ARCI)
大体时间:From baseline to 8 hours after administration
Obtained baseline and 1, 2, 4, 6 and 8-h after administration
From baseline to 8 hours after administration
Change in blood pressure
大体时间:From baseline to 8 hours after administration
Systolic and diastolic blood pressure (mmHg) will be measured obtained baseline and 0.5, 1, 1,5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in heart rate
大体时间:From baseline to 8 hours after administration
Heart rate (bpm) will be measured obtained baseline and 0.5, 1, 1,5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in oral temperature
大体时间:From baseline to 8 hours after administration
Oral temperature (ºC) will be measured obtained baseline and 0.5, 1, 1,5, 2, 3, 4, 6 and 8-h after administration.
From baseline to 8 hours after administration
Change in Maddox Wing score (MW)
大体时间:From baseline to 4 hours after administration
Maddox wing is a device for the measurement of diopters of horizontal heterophoria. From 22 (exophoria) to 15 (esophoria). Higher scores mean worse outcome.Obtained baseline and 1.5, 4-h after administration.
From baseline to 4 hours after administration
Hangover
大体时间:At 8 hours and 12 hours after administration
Measured at 8 and 12h , with Alcohol Hangover Severity Scale
At 8 hours and 12 hours after administration
Change in anxiety
大体时间:From baseline to 6 hours after administration
Measured with Anxiety-state scale (STAI-S) at baseline, 1,1,4, 6-h after administration
From baseline to 6 hours after administration
Beverage identification
大体时间:At 8 hours after administration
Beverage identification questionnaire.There is an option to select each treatment condition. Only measured at 8h after administration
At 8 hours after administration
Urine volume generated
大体时间:From baseline to 8 hours after administration
Mililiters of urine collected
From baseline to 8 hours after administration

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Clara Pérez Mañá, MD, PhD、Hospital Universitari Germans Trias i Pujol-IGTP

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月18日

初级完成 (估计的)

2027年3月1日

研究完成 (估计的)

2027年6月1日

研究注册日期

首次提交

2026年5月4日

首先提交符合 QC 标准的

2026年5月8日

首次发布 (实际的)

2026年5月14日

研究记录更新

最后更新发布 (实际的)

2026年5月14日

上次提交的符合 QC 标准的更新

2026年5月8日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

IPD will not be shared as the dataset is subject to ongoing analyses and planned future publications.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅